帕尼培南/倍他米隆治疗小儿难治性化脓性脑膜炎的疗效与安全性

目的:评价帕尼培南/倍他米隆治疗小儿难治性化脓性脑膜炎的临床疗效及安全性。方法:收集2011年7月至2017年7月我院儿科收治的难治性化脓性脑膜炎患儿63例,分成帕尼培南/倍他米隆组与美罗培南组,观察两组患儿的临床疗效和不良反应。结果:美罗培南组30例,有效率93. 33%,细菌培养阳性率为53. 33%,细菌清除率81. 25%;帕尼培南/倍他米隆组33例,总有效率90. 91%,细菌培养阳性率为57. 58%,细菌清除率84. 21%,两组患儿有效率、细菌培养阳性率、细菌清除率比较差异无统计学意义(P均>0. 05)。治疗后美罗培南组出现口腔白色念珠菌感染4例,帕尼培南/倍他米隆组出现3例,差异无统计学意义(P>0. 05)。所有患儿均未出现明显肝肾功能损伤,无过敏反应。结论:帕尼培南/倍他米隆治疗小儿难治性化脓性脑膜炎安全且疗效确切。

Panipenem/Betamipron in the Treatment of Refractory Suppurative Meningitis in Children

Objective: To evaluate the clinical efficacy and safety of panipenem/ betamipron in the treatment of refractory suppurativemeningitis in children. Methods: A total of 63 children with refractory suppurative meningitis admitted into the pediatrics of our hospital from Jul.2011 to Jul.2017 were extracted to be divided into the panipenem/ betamethamide group and the meropenem group, the clinical efficacy and adverse drug reactions of two groups were observed. Results: There were 30 cases in the meropenem group, the effective rate was 93.33%, the positive rate of bacterial culture was 53.33%, and the bacterial clearance rate was 81.25%; the panipenem/betamideron group was 33 cases, the effective rate was 90.91%, the positive rate of bacterial culture was 57.58%, and the bacterial clearance rate was 84.21%, with no statistically significant difference between two groups (P>0.05). After treatment, there were 4 cases of oral Candida albicans infection in the meropenem group and 3 cases in the panipenem/ betamipron group, the difference was not statistically significant (P>0.05). No obvious hepatic and renal function injury and no allergic reaction were observed in both groups. Conclusion: Panipenem/ betamipron is safe and effective in the treatment of refractory purulent meningitis in children.